Short Interest in INmune Bio, Inc. (NASDAQ:INMB) Rises By 7.8%

INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 4,000,000 shares, a growth of 7.8% from the November 30th total of 3,710,000 shares. Based on an average daily volume of 232,100 shares, the short-interest ratio is presently 17.2 days.

Wall Street Analyst Weigh In

Several analysts have issued reports on INMB shares. Alliance Global Partners began coverage on shares of INmune Bio in a research note on Monday, October 21st. They issued a "buy" rating and a $20.00 price objective for the company. Raymond James started coverage on INmune Bio in a research report on Friday, September 27th. They issued an "outperform" rating and a $18.00 price objective on the stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Sanctuary Advisors LLC purchased a new stake in shares of INmune Bio in the 3rd quarter worth approximately $113,000. Westside Investment Management Inc. lifted its holdings in INmune Bio by 57.3% during the third quarter. Westside Investment Management Inc. now owns 71,315 shares of the company's stock worth $384,000 after buying an additional 25,975 shares during the period. Barclays PLC boosted its position in INmune Bio by 601.9% during the 3rd quarter. Barclays PLC now owns 29,044 shares of the company's stock valued at $157,000 after acquiring an additional 24,906 shares in the last quarter. Geode Capital Management LLC raised its position in shares of INmune Bio by 6.6% in the 3rd quarter. Geode Capital Management LLC now owns 344,466 shares of the company's stock worth $1,857,000 after acquiring an additional 21,262 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of INmune Bio during the 3rd quarter worth $249,000. Hedge funds and other institutional investors own 12.72% of the company's stock.

INmune Bio Price Performance

Shares of NASDAQ:INMB traded up $0.02 during trading on Wednesday, reaching $4.67. 213,591 shares of the company were exchanged, compared to its average volume of 170,690. The firm has a market capitalization of $103.53 million, a PE ratio of -2.14 and a beta of 1.79. The business's fifty day simple moving average is $5.19 and its 200-day simple moving average is $6.26. INmune Bio has a 12-month low of $4.32 and a 12-month high of $14.74.

INmune Bio (NASDAQ:INMB - Get Free Report) last issued its earnings results on Thursday, October 31st. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.11). INmune Bio had a negative net margin of 26,333.59% and a negative return on equity of 117.48%. During the same period in the prior year, the business earned ($0.48) EPS. On average, sell-side analysts anticipate that INmune Bio will post -2.24 EPS for the current fiscal year.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.